Background/Aims: To identify the underlying molecular genetic cause of disease in a patient with Harboyan syndrome and to perform a detailed assessment of her renal function. We also assessed the influence of the SLC4A11 mutation identified on the corneal endothelium in the heterozygous state. Methods: A 55-year-old female was examined ophthalmologically, audiologically and nephrologically including 24-hour urine collection. The coding region of SLC4A11 was directly sequenced. Specular microscopy was performed in the proband's 21-year-old daughter. Results: The proband had bilateral iridectomy at the age of 3 months because of an initial diagnosis of congenital glaucoma and since the age of 12 years she underwent several keratoplasties in each eye. Nephrological examination did not reveal any abnormalities. Moderate bilateral sensorineural hearing loss was confirmed by audiometry. A novel homozygous mutation predicted to lead to a premature stop codon at the protein level, c.2188C>T; p.(Arg730*), was identified in SLC4A11. No changes in corneal endothelial cell morphology or density were observed in the heterozygous daughter. Conclusion: In contrast to the Slc4a11-/- mouse, no abnormalities in daily renal ion excretion or polyuria were observed in the Harboyan syndrome patient. The mutation identified does not affect corneal endothelial cell morphology or density in the heterozygous state. © 2014 S. Karger AG, Basel

Keywords:
Harboyan syndrome, SLC4A11, Corneal dystrophy, Sensorineural hearing loss, Kidney function tests
1.
Desir J, Abramowicz M: Congenital hereditary endothelial dystrophy with progressive sensorineural deafness (Harboyan syndrome). Orphanet J Rare Dis 2008;3:28.
2.
Desir J, Moya G, Reish O, Van Regemorter N, Deconinck H, David KL, Meire FM, Abramowicz MJ: Borate transporter SLC4A11 mutations cause both Harboyan syndrome and non-syndromic corneal endothelial dystrophy. J Med Genet 2007;44:322-326.
3.
Vithana EN, Morgan P, Sundaresan P, Ebenezer ND, Tan DT, Mohamed MD, Anand S, Khine KO, Venkataraman D, Yong VH, Salto-Tellez M, Venkatraman A, Guo K, Hemadevi B, Srinivasan M, Prajna V, Khine M, Casey JR, Inglehearn CF, Aung T: Mutations in sodium-borate cotransporter SLC4A11 cause recessive congenital hereditary endothelial dystrophy (CHED2). Nat Genet 2006;38:755-757.
4.
Riazuddin SA, Vithana EN, Seet LF, Liu Y, Al-Saif A, Koh LW, Heng YM, Aung T, Meadows DN, Eghrari AO, Gottsch JD, Katsanis N: Missense mutations in the sodium borate cotransporter SLC4A11 cause late-onset Fuchs corneal dystrophy. Hum Mutat 2010;31:1261-1268.
5.
Vithana EN, Morgan PE, Ramprasad V, Tan DT, Yong VH, Venkataraman D, Venkatraman A, Yam GH, Nagasamy S, Law RW, Rajagopal R, Pang CP, Kumaramanickevel G, Casey JR, Aung T: SLC4A11 mutations in Fuchs endothelial corneal dystrophy. Hum Mol Genet 2008;17:656-666.
6.
Parker MD, Ourmozdi EP, Tanner MJ: Human BTR1, a new bicarbonate transporter superfamily member and human AE4 from kidney. Biochem Biophys Res Commun 2001;282:1103-1109.
7.
Jalimarada SS, Ogando DG, Vithana EN, Bonanno JA: Ion transport function of SLC4A11 in corneal endothelium. Invest Ophthalmol Vis Sci 2013;54:4330-4340.
8.
Vilas GL, Loganathan SK, Liu J, Riau AK, Young JD, Mehta JS, Vithana EN, Casey JR: Transmembrane water flux through SLC4A11: a route defective in genetic corneal diseases. Hum Mol Genet 2013;22:4579-4590.
9.
Liu J, Seet LF, Koh LW, Venkatraman A, Venkataraman D, Mohan RR, Praetorius J, Bonanno JA, Aung T, Vithana EN: Depletion of SLC4A11 causes cell death by apoptosis in an immortalized human corneal endothelial cell line. Invest Ophthalmol Vis Sci 2012;53:3270-3279.
10.
Gröger N, Fröhlich H, Maier H, Olbrich A, Kostin S, Braun T, Boettger T: SLC4A11 prevents osmotic imbalance leading to corneal endothelial dystrophy, deafness, and polyuria. J Biol Chem 2010;285:14467-14474.
11.
Han SB, Ang HP, Poh R, Chaurasia SS, Peh G, Liu J, Tan DT, Vithana EN, Mehta JS: Mice with a targeted disruption of Slc4a11 model the progressive corneal changes of congenital hereditary endothelial dystrophy. Invest Ophthalmol Vis Sci 2013;54:6179-6189.
12.
Lopez IA, Rosenblatt MI, Kim C, Galbraith GC, Jones SM, Kao L, Newman D, Liu W, Yeh S, Pushkin A, Abuladze N, Kurtz I: Slc4a11 gene disruption in mice: cellular targets of sensorineuronal abnormalities. J Biol Chem 2009;284:26882-26896.
13.
Provan D: Oxford Handbook of Clinical and Laboratory Investigation. Oxford, Oxford University Press, 2010.
14.
den Dunnen JT, Antonarakis SE: Nomenclature for the description of human sequence variations. Hum Genet 2001;109:121-124.
15.
Liskova P, Filipec M, Merjava S, Jirsova K, Tuft SJ: Variable ocular phenotypes of posterior polymorphous corneal dystrophy caused by mutations in the ZEB1 gene. Ophthalmic Genet 2010;31:230-234.
16.
Galgauskas S, Krasauskaite D, Pajaujis M, Juodkaite G, Asoklis RS: Central corneal thickness and corneal endothelial characteristics in healthy, cataract, and glaucoma patients. Clin Ophthalmol 2012;6:1195-1199.
17.
Ramprasad VL, Ebenezer ND, Aung T, Rajagopal R, Yong VH, Tuft SJ, Viswanathan D, El-Ashry MF, Liskova P, Tan DT, Bhattacharya SS, Kumaramanickavel G, Vithana EN: Novel SLC4A11 mutations in patients with recessive congenital hereditary endothelial dystrophy (CHED2). Mutation in brief #958. Online. Hum Mutat 2007;28:522-523.
18.
Vilas GL, Morgan PE, Loganathan SK, Quon A, Casey JR: A biochemical framework for SLC4A11, the plasma membrane protein defective in corneal dystrophies. Biochemistry 2011;50:2157-2169.
19.
Mehta JS, Hemadevi B, Vithana EN, Arunkumar J, Srinivasan M, Prajna V, Tan DT, Aung T, Sundaresan P: Absence of phenotype-genotype correlation of patients expressing mutations in the SLC4A11 gene. Cornea 2010;29:302-306.
20.
Hemadevi B, Veitia RA, Srinivasan M, Arunkumar J, Prajna NV, Lesaffre C, Sundaresan P: Identification of mutations in the SLC4A11 gene in patients with recessive congenital hereditary endothelial dystrophy. Arch Ophthalmol 2008;126:700-708.
21.
Kodaganur SG, Kapoor S, Veerappa AM, Tontanahal SJ, Sarda A, Yathish S, Prakash DR, Kumar A: Mutation analysis of the SLC4A11 gene in Indian families with congenital hereditary endothelial dystrophy 2 and a review of the literature. Mol Vis 2013;19:1694-1706.
22.
Meire FM, Pantelis V, Schuil J: Comment on ‘A further observation of corneal dystrophy and perceptive deafness in two siblings'. Ophthalmic Genet 1998;19:105-106.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.